Incyte Corporation
NASDAQ:INCYBiotechnology
-$0.77 today
- Market cap
- $24.01B
- Beta
- 0.79
- P/E (TTM)
- 13.7
- EPS (TTM)
- $7.18
Volume 1.21M
Average 1.58M
INCY Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Incyte CorporationNASDAQ: INCY
Revenue · Q2 FY2026 · quarter ended Jun 2026
Revenue growth accelerates
Q2 FY2026 revenue of $1.67B rose 37.7% year over year, ahead of the +26.9% change in trailing-twelve-month revenue. Sequentially, it rose 31.5% from the prior quarter. Over 3 fiscal years it compounded at +14.8% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 17 analysts of $6.04B (+17.6%) for the fiscal year ending Dec 2026, a slowdown from the +21.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $1.67B+31.5% QoQ
- Last fiscal yearDec 2025
- $5.14B+21.2% YoY
- LTMJun 2026
- $5.82B+26.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +37.7% | +7.2% | -30.5 pp |
| 1 year | +21.2% | +17.6% | -3.7 pp |
| 3-year CAGR | +14.8% | +8.4% | -6.4 pp |
| 5-year CAGR | -0.0% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 5.14B USD
- Year-over-year change
- +21.2%
- 4-year CAGR
- +14.5%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.14B | +21.2% |
| FY2024 | 2024-12-31 | 4.24B | +14.8% |
| FY2023 | 2023-12-31 | 3.7B | +8.9% |
| FY2022 | 2022-12-31 | 3.39B | +13.7% |
| FY2021 | 2021-12-31 | 2.99B | — |
Revenue vs competitors
How INCY compares with its peers on the latest reported figures
- INCY's LTM Jun 2026 revenue of $5.82B is the 2nd highest of the 11 companies compared; the peer median is $496.24M.
- Its year-over-year change of +26.9% is the 5th highest of 7, against a peer median of +52.2%.
- Over three fiscal years its annual growth of +14.8% compares with a peer median of +12.9%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $15.53B | +9.3% | +5.6% | |
| LTM Jun 2026 | $5.82B | +26.9% | +14.8% | |
| LTM Jun 2026 | $4.13B | — | -36.4% | |
| LTM Jul 2026 | $2.44B | +9.2% | +12.9% | |
| LTM Sep 2026 | $1.36B | +49.5% | +106.4% | |
| LTM Aug 2026 | $701.94M | +738.8% | +29.5% | |
| LTM Jun 2026 | $290.54M | +54.9% | +11.0% | |
| LTM Mar 2026 | $49.59M | +395.8% | +128.4% | |
| LTM Sep 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
| Peer median (excluding INCY) | $496.24M | +52.2% | +12.9% | |
Competitors are the stored peer set for INCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.99B | 3.39B | 3.7B | 4.24B | 5.14B |
| Cost of Revenue | 150.99M | 207M | 254.99M | 312.1M | 372.1M |
| Gross Profit | 2.84B | 3.19B | 3.44B | 3.93B | 4.77B |
| Gross Margin | 94.9% | 93.9% | 93.1% | 92.6% | 92.8% |
| Research & Development | 1.46B | 1.59B | 1.63B | 2.61B | 2.05B |
| Selling, General & Admin | 739.56M | 1B | 1.16B | 1.22B | 1.38B |
| Operating Expenses | 2.25B | 2.6B | 2.79B | 3.83B | 3.43B |
| Depreciation & Amortization | 57.84M | 67.86M | 82.66M | 89.25M | 93.29M |
| EBITDA | 630.2M | 599.64M | 919.43M | 408.16M | 1.76B |
| EBITDA Margin | 21.1% | 17.7% | 24.9% | 9.6% | 34.2% |
| Operating Income | 585.78M | 591.63M | 655.36M | 101.29M | 1.34B |
| Operating Margin | 19.6% | 17.4% | 17.7% | 2.4% | 26.1% |
| Interest Income | 0 | 0 | 0 | 128.71M | 105.6M |
| Interest Expense | 1.91M | 2.67M | 2.55M | 2.28M | 2.43M |
| Other Income / Expenses | (15.33M) | (62.51M) | 178.86M | 215.34M | 321.66M |
| Income Before Tax | 570.44M | 529.12M | 834.22M | 316.63M | 1.66B |
| Pre-Tax Margin | 19.1% | 15.6% | 22.6% | 7.5% | 32.4% |
| Income Tax Expense | (378.14M) | 188.46M | 236.62M | 284.02M | 377.8M |
| Net Income | 948.58M | 340.66M | 597.6M | 32.62M | 1.29B |
| Net Margin | 31.8% | 10.0% | 16.2% | 0.8% | 25.0% |
| EPS (Basic) | 4.30 | 1.53 | 2.67 | 0.16 | 6.59 |
| EPS (Diluted) | 4.27 | 1.52 | 2.65 | 0.15 | 6.41 |
| Weighted Avg Shares | 220.43M | 222M | 223.63M | 207.11M | 195.2M |
| Weighted Avg Shares (Diluted) | 222.07M | 223.96M | 225.93M | 210.53M | 200.7M |
Incyte Corporation
NASDAQ:INCY
Intrinsic Alpha fair value
Locked
Current Price
$117.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.